CoChat

Drug repurposing screens identify chemical entities for the development of COVID-19 interventions

Open access
Bakowski, Malina A., Beutler, Nathan, Wolff, Karen C., Kirkpatrick, Melanie G., Chen, Emily, Nguyen, Tu-Trinh H., Riva, Laura, Shaabani, Namir, Parren, Mara, Ricketts, James, Gupta, Anil K., Pan, Kastin, Kuo, Peiting, Fuller, MacKenzie, Garcia, Elijah, Teijaro, John R., Yang, Linlin, Sahoo, Debashis, Chi, Victor, Huang, Edward, Vargas, Natalia, Roberts, Amanda J., Das, Soumita, Ghosh, Pradipta, Woods, Ashley K., Joseph, Sean B., Hull, Mitchell V., Schultz, Peter G., Burton, Dennis R., Chatterjee, Arnab K., McNamara, Case W., Rogers, Thomas F. · 2021 · Nature Communications
Cited by 138

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

The ongoing pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), necessitates strategies to identify prophylactic and therapeutic drug candidates for rapid clinical deployment. Here, we describe a screening pipeline for the discovery of efficacious SARS-CoV-2 inhibitors. We screen a best-in-class drug repurposing library, ReFRAME, against two high-throughput, high-content imaging infection assays: one using HeLa cells expressing SARS-CoV-2 receptor ACE2 and the other using lung epithelial Calu-3 cells. From nearly 12,000 compounds, we identify 49 (in HeLa-ACE2) and 41 (in Calu-3) compounds capable of selectively inhibiting SARS-CoV-2 replication. Notably, most screen hits are cell-line specific, likely due to different virus entry mechanisms or host cell-specific sensitivities to modulators. Among these promising hits, the antivirals nelfinavir and the parent of prodrug MK-4482 possess desirable in vitro activity, pharmacokinetic and human safety profiles, and both reduce SARS-CoV-2 replication in an orthogonal human differentiated primary cell model. Furthermore, MK-4482 effectively blocks SARS-CoV-2 infection in a hamster model. Overall, we identify direct-acting antivirals as the most promising compounds for drug repurposing, additional compounds that may have value in combination therapies, and tool compounds for identification of viral host cell targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-23328-0

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 138

Metadata

Authors
Bakowski, M. A., Beutler, N., Wolff, K. C., Kirkpatrick, M. G., Chen, E., Nguyen, T.-T. H., Riva, L., Shaabani, N., Parren, M., Ricketts, J., Gupta, A. K., Pan, K., Kuo, P., Fuller, M., Garcia, E., Teijaro, J. R., Yang, L., Sahoo, D., Chi, V., Huang, E., Vargas, N., Roberts, A. J., Das, S., Ghosh, P., Woods, A. K., Joseph, S. B., Hull, M. V., Schultz, P. G., Burton, D. R., Chatterjee, A. K., McNamara, C. W., & Rogers, T. F.
Venue
Nature Communications
Published
2021-06-03
Volume
12
Issue
1
Pages
3309-3309
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3165248908
Cited by
138
References
7
FWCI
8.44
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. https://app.cochat.ai/papers/10.1038/s41467-021-23328-0
The paper
Bakowski, M. A., Beutler, N., Wolff, K. C., Kirkpatrick, M. G., Chen, E., Nguyen, T.-T. H., Riva, L., Shaabani, N., Parren, M., Ricketts, J., Gupta, A. K., Pan, K., Kuo, P., Fuller, M., Garcia, E., Teijaro, J. R., Yang, L., Sahoo, D., Chi, V., . . . Rogers, T. F. (2021). Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. Nature Communications. https://doi.org/10.1038/s41467-021-23328-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.